Bridge Laboratories

Kirkegaard & Perry Laboratories (KPL) provides protein detection technologies, reagents and systems with support services to life science researchers and commercial partners throughout the world. The company develops, manufactures and markets immunochemicals for life science and in vitro diagnostics. KPL was one of the first companies to commercialize affinity-purified, secondary antibodies for biological research and in vitro diagnostic testing. The company has introduced more than 600 reagents and complete assay kits for protein visualization and nucleic acid detection that address the needs of cell biology, immunology, protein chemistry and molecular biology scientists. Many leading diagnostic kit manufacturers utilize KPL reagents in a variety of diagnostic kits for AIDS, tropical diseases, food testing and cancer. The company was founded in 1979 and is located in Gaithersburg, Md.

Histoserv Inc, located in Germantown, MD, specializes in providing high-quality histology services and products. The company is affiliated with numerous prestigious institutions, including the National Institutes of Health, Cornell University, and Johns Hopkins University, reflecting its commitment to excellence in the field. With a focus on innovation and collaboration, Histoserv Inc serves a diverse clientele, including universities and research organizations. Their dedication to advancing histological research is evident through partnerships with leading entities such as Regeneron and the Howard Hughes Medical Institute. Generated from the website

Sequella Inc. is a clinical-stage pharmaceutical company based in Rockville, MD, focused on developing innovative antibiotics to combat drug-resistant bacterial, fungal, and parasitic infections. Their product pipeline addresses significant global health threats, particularly tuberculosis and its multidrug-resistant forms, which impact billions of people worldwide. With two drug candidates having completed phase 2 clinical trials and additional candidates in preclinical development, Sequella aims to tackle various infectious diseases, including Helicobacter pylori infections and Clostridium difficile. Their research also explores treatments for non-tuberculous mycobacterial infections and parasitic diseases, demonstrating a commitment to addressing critical health challenges globally. Generated from the website